Familial hypertrophic cardiomyopathy (HCM), frequently caused by sarcomeric gene mutations, is characterized by cellular dysfunction and asymmetric left ventricular (LV) hypertrophy. We studied whether cellular dysfunction is due to an intrinsic sarcomere defect or cardiomyocyte remodeling.
Introduction
Familial hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disorder affecting 0.2% of the adult population and is the main cause of sudden cardiac death in young individuals. 1 HCM is characterized by asymmetric left ventricular hypertrophy (LVH), mostly occurring in the interventricular septum (IVS). 1 Mutations have been identified in 13 different genes, which frequently encode for sarcomeric proteins. Over 80% of the mutations resides in the genes MYH7 and MYBPC3, which encode the thick filament proteins β-myosin heavy chain (β-MHC) and cardiac myosin-binding protein-C (cMyBP-C). 2, 3 Mutations in the genes encoding thin filament proteins TNNT2 (cardiac troponin T; cTnT), TNNI3 (cardiac troponin I, cTnI), TNNC1 (cardiac troponin C; TnC) and TPM1 (tropomyosin, TM) have a prevalence of approximately 10%. 2, 3 Since genetic screening improved over the past 20 years, sarcomere mutations can be detected at an early stage in healthy family members (mutation carriers) of manifest HCM patients. Although mutation carriers can be identified before the onset of the disease, no treatment is available to prevent HCM. Development of (preventive) drug therapies requires insight in the pathomechanisms leading from the genotype (mutation) to the HCM phenotype.
Recent studies [4] [5] [6] [7] [8] demonstrated that regional myocardial dysfunction is already present in otherwise healthy mutation carriers without significant septal hypertrophy. Cardiac dysfunction was most evident in the non-hypertrophied LV lateral wall of mutation carriers. 5 These findings suggest that impaired cardiac contractile function precedes the process of cardiac remodeling, characterized by the typical asymmetric LVH, fibrosis and cardiomyocyte disarray. 9 Cardiac contractile dysfunction in mutation carriers may be caused by the affected sarcomeric protein. As thick and thin filament proteins have highly diverse regulatory roles in sarcomere contraction, 10 the initial functional changes caused by the sarcomere mutations may differ dependent on the affected gene. However, due to extensive cardiac remodeling, it is difficult to assess the intrinsic properties of mutant sarcomeres. Early investigations on structural changes in the heart of HCM patients reported cellular hypertrophy and myofibril lysis, 11 which may cause cellular dysfunction and mask the intrinsic functional properties of the affected sarcomeres. To improve our understanding of HCM pathophysiology and the complex genotype-phenotype relation, we need to discern cellular remodeling from mutation-related intrinsic sarcomere defects in patients with manifest HCM. The aim of the present study was to investigate to what extent sarcomeric gene mutations and cellular remodeling in HCM underlie changes in the force generating capacity of cardiomyocytes.
Methods

Cardiac tissue
Tissue was obtained from the LV interventricular septum (IVS) of 54 familial hypertrophic cardiomyopathy (HCM) patients during myectomy (Morrow) surgery to relieve LV outflow obstruction in The Netherlands or in Italy. LV systolic function was graded as normal (grade 1), while impaired relaxation was observed in all patients. 12 Patients received a combination of β-blockers, diuretics, statins and anti-arrhythmic agents as medication.
Of this patient group 41 carried a mutation in genes encoding sarcomeric proteins (HCM mut group). This group comprised 28 patients with a heterozygous MYBPC3 mutation, 9 patients harboring MYH7 missense mutations, 1 patient with a heterozygous TPM1 mutation and 2 patients with a heterozygous TNNI3 missense mutation. In addition, IVS tissue was obtained from an explanted heart harboring a homozygous TNNT2 mutation.
In 14 HCM patients no mutation was found after detailed sequencing of 8 HCMassociated genes (MYBPC3, MYH7, TNNT2, TNNI3, MYL2, ACTC, TPM1 and TNNC1). 3 These patients served as control group, i.e. sarcomere mutation negative patient group (HCM smn ).
In addition, IVS samples were obtained from patients with LV hypertrophy due to aortic stenosis (LVH ao , N=8; 67±5 years of age, 2/6 male/female) and non-failing cardiac tissue from the free LV wall from donor hearts (N=13; 37±10 years of age, 10/3 male/female) when no suitable transplant recipient was found. The donors had no history of cardiac disease, a normal cardiac examination, a normal ECG and normal ventricular function on echocardiography within 24 hours of heart explantation. All tissue samples were immediately frozen and stored in liquid nitrogen. The study protocol was approved by the local ethics committees and written informed consent was obtained.
Force measurements in single cardiomyocytes
Force measurements on single cardiomyocytes were performed as described previously. 13 In short, cells were treated with 0.5% Triton X-100 to dissolve the membranes, which allowed us to directly assess the maximal force generating capacity of the myofilaments without interference of Ca 2+ -handling proteins. Membrane-permeabilized cardiomyocytes were mounted between a force transducer and a piezoelectric motor ( Figure 1A ) and stretched to a sarcomere length of 2.2 μm. Maximal isometric force development (F max ) was measured in activating solution with a [ Ca   2+ ] of 31.62 μmol/L. After transfer of the cardiomyocyte to activating solution, force development increased ( Figure 1B ). When the steady force level was reached the cardiomyocyte was shortened by 30% to determine total force development (F total ). Subsequently, the cardiomyocyte was transferred to relaxing solution (10 -6 μmol/L calcium) in which a second slack was performed to assess passive force development (F pas ). F max was calculated by subtracting F pas from F total . Force values were normalized to crosssectional area (CSA) of the cardiomyocytes, which was calculated on the basis of cardiomyocyte width and depth (i.e. CSA = width x depth x π/4). In addition, the CSA provides information on the degree of cellular hypertrophy. Force signals were analyzed using Labview version 9.0 (National Instruments Corporation, Austin, TX). force registration of a MYBPC3 mut cardiomyocyte. After reaching a maximal steady force level the cardiomyocyte was shortened by 30% and immediately re-stretched to its original length to determine the baseline of force and assess the total force developed (F total ). Subsequently, a second slack was performed in the relaxing solution to assess passive force development (F pas ). F max was calculated by subtracting F pas from F total .
Force measurements in single cardiac myofibrils
Force measurements on single myofibrils were performed as described previously. 14 In short, LV tissue was cut into thin strips in rigor solution containing (in mmol/L: NaCl 132, KCl 5, MgCl 2 1, Tris 10, EGTA 5 (pH 7.1). The strips were treated with 1% Triton X-100 to dissolve the membranes. After removal of Triton, the strips were homogenized in rigor solution to obtain a myofibril suspension. A small volume of the myofibril suspension was transferred to a temperature-controlled chamber (15 ºC) filled with relaxing solution (pCa 8.0) and mounted on an inverted microscope. Selected preparations (single myofibrils or bundles of few myofibrils, 25-80 μm long, 1-4 μm wide) were mounted horizontally between two glass microtools ( Figure 7A ). One tool was connected to a length-control motor that could produce rapid (<1 ms) length changes. The second tool was a calibrated cantilevered force probe (2-6 nm nN−1; frequency response 2-5 kHz). Force was measured from the deflection of the image of the force probe projected on a split photodiode. Average sarcomere length and myofibril diameter were measured from video images (magnification 1800x). The initial sarcomere length of the preparations was set around 2.2 μm. F max of the myofibrils was measured in a flowing stream of activating solution with a calcium concentration of 31.62 μmol/L across the length of the preparation.
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Histological analyses
Myocardial tissue obtained from 18 HCM mut , 5 HCM smn patients and 11 non-failing donor hearts were formalin fixed (pH 7.0), and sectioned at 5 µm. Additional analysis of CSA was performed using a Wheat Germ Agglutinin (WGA) staining and a Haematoxylin and Eosin (HE) staining. Photomicrographs were obtained (Leitz DMRXE; Leica, Wetzlar, Germany) and the CSA of at least 70 representative delineated cardiomyocytes per patient was quantified as width x depth x π/4 using ImageJ 1.45s software (National Institute of Health, USA).
The amount of fibrosis in the samples was quantified using Picrosirius Red staining. Photomicrographs were obtained (Leica DM 2000; Leica, Wetzlar, Germany) and fibrosis was quantified as a percentage of the total slide area using ImageJ 1.45s software.
Electron microscopy (EM) was used to quantify cardiomyocyte myofibrillar density in all groups as described previously. 16, 17 In short, a small piece of cardiac tissue was fixed in 2%
(vv) gluteraldehyde for 30 min. and 1.5% (w/v) osmium tetroxide for 10 min, dehydrated with acetone and embedded in Epon812. Ultrathin sections were collected on a 300-meh Formavar-coated Nickel-grid. Before examination on a Jeol-1200EX electron microscope the sections were contrasted with uranyl acetate. As it was important to obtain images showing a large area of each cardiomyocyte to accurately determine myofibril density, a magnification of 3600x was used. This magnification provided us with a large part of each single cardiomyocyte with clearly visible and distinguishable myofibrils. Myofibril density from 5 to 10 representative cardiomyocytes (or at least a large part of the cardiomyocyte) per sample was calculated as the sum of the myofibril area related to total area and expressed as a percentage of total cardiomyocyte area using Slidebook™ 5.0 software (3I, Denver, Co). As two mutation groups existed of only one patient the repeated sample assessments was taken into account using multilevel analysis. This analysis is only valid for data sets following a normal distribution. When this was not the case, the data set was logarithmictransformed which led to data sets following a normal distribution. For this purpose a linear mixed model procedure was used (SPSS version 15.0, IBM, Armonk, NY, USA) P<0.05 was considered significant. 95% confidence intervals were calculated to gain insight in the range of the mean differences between the groups and are provided in a supplement. In case of logarithmic transformed data sets 95% confidence intervals (CIs) were calculated by taking the exponential of the natural logarithmic values. The CIs reflect ratios stating that the mean difference between two groups can be [x to y] time higher or lower than the group of comparison. Exact P-values and 95% confidence intervals regarding each analysis are provided in the Supplementary material (Tables 1-4) . Table 1 shows that the included patients harbored a truncation or a missense mutation. Previous studies showed that truncation mutations lead to haploinsufficiency (reduced expression of full length protein) without incorporation of the truncated mutant protein. 18, 19 Missense mutations lead to poison peptides, which are incorporated in the sarcomere. 20, 21 Hypertrophic obstructive cardiomyopathy was evident from the high septal thickness (normal value <13 mm) 22 and high LV outflow tract pressure gradient (normal value <30 mm Hg) 9 and did not differ between HCM mut and HCM smn patients. 
Data analysis and statistics
Results
Clinical characteristics
Maximal force generating capacity of cardiomyocytes
Single cardiomyocyte force measurements ( Figure 1A&B ) were performed to investigate the maximal force generating capacity (F max ) in sarcomere mutation-positive HCM compared to hypertrophied control groups (HCM smn and LVH ao ) and non-failing donors. The assumption of normality was not violated when F max data sets per mutation group were tested (P<0.05). Overall, multilevel analysis revealed a significantly lower F max in all sarcomere mutationpositive groups compared with donors ( Figure 2A ). In addition, MYH7 mut and TPM1 mut had significantly lower F max values compared with HCM smn . Moreover, F max was significantly lower in HCM smn compared with donors.
Degree of cardiomyocyte hypertrophy
Width and depth of the cardiomyocytes were determined in the cardiomyocyte set-up ( Figure 1A ) to calculate CSA assuming an elliptical cross-section. Testing the CSA data per group revealed a violation of the normality assumption (P<0.05) leading to a logarithmic transformation of the data for clear interpretation. As visualized in Figure 2B multilevel analysis revealed significantly higher CSA in all sarcomere mutation-positive groups compared with donor and LVH ao . Interestingly, CSA was significantly higher in TPM1 mut , TNNI3 mut and TNNT2 mut compared with HCM smn .
To further investigate a possible difference in the extent of cardiomyocyte hypertrophy between HCM mut and HCM smn , histological analysis was performed to determine CSA in WGA-stained tissue sections in a subset of patients and donors ( Figure 3A&B ). The non-parametrical Kruskal Wallis test and Dunn's procedure revealed a significantly higher CSA in HCM mut compared with HCM smn and LVH ao . In addition, the CSA of both the HCM smn and LVH ao was significantly larger compared with donor. Similar results were obtained with Haematoxylin and Eosin stained tissue sections (Supplementary material Figure 1A&B ).
Fibrosis
On an average the amount of fibrosis, stained with Picrosirius Red, was significantly higher in HCM mut compared with donor hearts ( Figure 3D ). The percentage of fibrosis in the HCM smn group did not differ from the other groups, although one patient showed a high amount of fibrosis. In Figure 3E F max was plotted against the amount of fibrosis in each individual heart. This figure illustrates that there is no clear relation between the amount of fibrosis and the maximal force generating capacity of cardiomyocytes. Interestingly, in addition to low cardiomyocyte force generation the MYH7 mut samples (N=4) hardly showed any fibrosis. These data suggest that fibrosis is not a major contributor to impaired cardiomyocyte performance in HCM. 
P<0.05) E.
Average fibrosis per heart sample plotted as the function of the mean maximal force generating capacity of the same heart. There is no correlation between these parameters.
Myofibrillar density
To investigate if reduced myofibrillar density underlies low cardiomyocyte F max in hypertrophied hearts we analyzed myofibrillar density in 18 sarcomere mutation-positive HCM hearts, 8 HCM smn , 2 LVH ao and 5 donor hearts. Figure 4A shows 2 representative EM images. The numbers indicate different cellular structures: 1) myofibrils, 2) glycogen and mitochondria deposits, 3) nucleus, 4) lipofuscin and 5) cell border. Lipofuscin is a sign of cell aging and not typical for HCM. It exists of protein degradation products, which are neither lysosomal degradable nor subject to endocytosis. 23 The area between the dashed white lines was taken as cardiomyocyte area. In this area the myofibrils were masked and myofibrillar density was calculated by the sum of masked myofibril areas relative to the cardiomyocyte area and expressed as a percentage. 16, 17 The data sets passed the normality test (P>0.05).
Multilevel analysis revealed that myofibrillar density was significantly lower in HCM mut samples compared with HCM smn and donors ( Figure 4B ). Myofibrillar density of HCM smn was significantly lower compared with donors, while LVH ao had a significantly lower myofibrillar density compared with HCM smn and donors. In Figure 4C the average myofibrillar density per heart sample is plotted as the function of the corresponding averaged cardiomyocyte cross-sectional area of the same heart (data from Figure 1B ). Compared with donor hearts, positioned between the grey dashed square, the distribution of cardiomyocyte CSA of HCM mut hearts was more heterogeneous. In addition, this figure illustrates that in several samples cellular myofibrillar density lags behind when cardiomyocytes are more hypertrophied evident from the samples positioned at the right site of the figure. In the LVH ao samples the CSA was relatively normal compared with the donors, while myofibrillar density was lower. .0001). N= number of patients and n= number of cardiomyocytes. C. Average myofibrillar density per heart sample plotted as a function of the mean CSA of the same heart for the different groups. Both the average CSA and myofibrillar density in donor samples varied within a relatively narrow range, which is indicated by the grey dashed square. The CSA was heterogeneously distributed among all HCM mut groups.
Correction of cardiomyocyte maximal force by myofibrillar density
To reveal to what extent the decrease in F max in HCM compared with non-failing cardiomyocytes (Figure 2A ) is caused by a reduction in myofibrillar density or can be attributed to the underlying sarcomeric gene mutation, we corrected F max of a subset of hearts by the matched myofibrillar density. Due to limited tissue availability myofibrillar density could not be analyzed for all hearts, in which also cardiomyocyte force measurements were performed. In this case the assumption of normality was again violated (P<0.05) leading to a logarithmic transformation. Figure 5 shows the average value of F max corrected by the corresponding myofibrillar density of each heart. This figure illustrates that the low F max in cardiomyocytes bearing mutations in MYBPC3 and TNNI3 was mostly due to a decrease in myofibrillar density. In contrast, in hearts with mutations in MYH7, TPM1 and TNNT2 the decrease in F max can also partly be attributed to the underlying sarcomeric gene mutations. F max corrected by myofibrillar density was significantly lower for MYH7 mut and TPM1 mut compared with HCM smn and donors. 
Force generation in single myofibrils
While cardiomyocyte force corrected by myofibrillar density is an indirect measure of myofibril force, single myofibril measurements provide insight in force production per myofibril independent of cellular hypertrophy. Therefore, we also measured maximal force in single myofibrils ( Figure 6A ) from 20 sarcomere mutation-positive HCM samples, 3 HCM smn , 7 LVH ao and 4 non-failing donor hearts ( Figure 6B ). The assumption of normality was not violated (P>0.05). Multilevel analysis revealed a significant reduction of F max of myofibrils of all HCM mut groups, except TNNI3 mut , compared with donor. A significant reduction in F max was also observed in myofibrils isolated from HCM smn and LVH ao samples compared with the donors, indicating that part of the reduced F max is aspecific and characteristic for cardiac remodeling. In accordance with our cardiomyocyte measurements of F max (corrected for myofibrillar density; Figure 4 ) myofibril F max values were lowest in MYH7 mut and TPM1 mut samples. 
Force development in MYH7 mut cardiomyocytes at submaximal [Ca
2+ ]
In particular MYH7 mut cardiomyocytes showed a low F max after correction for myofibrillar density. Low F max was confirmed in single MYH7 mut myofibrils. All force measurements were performed at saturating (maximal) [Ca 2+ ], while submaximal [Ca 2+ ] levels represent a more physiological condition. Therefore, we also performed force measurements at submaximal [Ca 2+ ] in MYH7 mut cardiomyocytes to determine whether a decrease in force development is also present at more physiologic [Ca 2+ ]. Importantly, our previous studies showed higher myofilament Ca 2+ -sensitivity in HCM compared with donor, which was absent after treatment with protein kinase A (PKA), the downstream kinase of the β-adrenergic receptors, ] ( Figure 7B ), taking into account cellular remodeling and differences in PKA-phosphorylation background between the groups. Figure 6B illustrates that MYH7 mutations result in hypocontractile sarcomeres at both maximal and more physiological submaximal [Ca 2+ ].
Discussion
Our study revealed a significant decrease in maximal force generating capacity of cardiomyocytes from HCM tissue harboring mutations in genes encoding thick and thin filament proteins compared with non-failing donor myocardium. We investigated if this reduction was due to the sarcomeric gene mutations or to structural changes of the heart muscle. An up to 2-fold increase in the degree of cellular hypertrophy and a decrease of more than 15% in myofibrillar density was found in HCM mut compared with non-failing donors. Correction for reduced myofibrillar density largely normalized F max in MYBPC3 mut and TNNI3 mut to values observed in donors. However, low maximal force generating capacity was revealed in hearts bearing heterozygous MYH7 and TPM1 mutations, and a homozygous TNNT2 mutation, which was confirmed by force measurements in single cardiac myofibrils. This hypocontractile sarcomere phenotype was also evident at submaximal [Ca 2+ ] in HCM with mutations in MYH7. Our data indicate that hypocontractile sarcomeres may represent a primary abnormality in HCM caused by mutations in the MYH7 gene.
Cardiomyocyte remodeling in HCM
One of the main HCM structural characteristics is LV hypertrophy, which is asymmetric and often most severe in the IVS. 1, 2 All HCM patients included in the present study had hypertrophic obstructive cardiomyopathy evident from the high septal thickness (Table 1 ). In line with increased septal thickness, a higher cardiomyocyte size was found in HCM compared with non-failing donor myocardium ( Figure 2B ). Interestingly, the septal thickness of the included MYH7 mut patients in the present study was significantly higher in the MYH7 mut (27±2 mm) compared with the MYBPC3 mut (23±1 mm) patient group, while MYH7 mut patients were slightly younger at the time of surgery. Accordingly, age of disease onset has been reported to be lower MYH7 compared with MYBPC3 patients. 24, 25 Our study showed less cardiomyocyte hypertrophy in HCM smn compared with HCM mut (Figure 3 ), while septal thickness was similar in these patient groups (Table 1 ). This suggests that in addition to cellular hypertrophy for, IVS hypertrophy in sarcomere mutation-negative HCM patients may be due to expansion of the extracellular matrix.
Since asymmetric hypertrophy in HCM reflects a concentric type of cardiac remodeling, one would expect that the myofilament proteins are added in series leading to thickening of the ventricular wall. 26 However, a significant decrease in myofibrillar density was found in HCM mut , HCM smn and LVH ao compared with donor myocardium ( Figure 3B ). The reduction in myofibrillar density may be explained by impaired synthesis of myofilaments or enhanced proteolysis. In several patients cardiomyocyte hypertrophy was extremely high compared with donors evident from the samples positioned at the right site of Figure 4C . In some of these samples myofibrillar density was very low suggesting that de novo synthesis of myofibrils is reduced or at least insufficient to match the extreme cellular growth. Several samples with less extremely hypertrophied cells also showed a very low myofibrillar density compared with donor and HCM smn samples ( Figure 4C ). As the degree of cellular hypertrophy is not extreme in these samples, the reduction in myofibrillar density may rather be explained by myofibril lysis. Myofibrillar lysis was also seen in transgenic mice carrying TNNT2 mutations and human LV tissue harboring a MYH7 mutation. 27, 28 Accordingly, all HCM mut showed a lower myofibrillar density compared with donor and HCM smn samples. As myofibrillar density was lower in HCM mut compared with HCM smn with similar cardiomyocyte cell size, the even larger reduction in myofibrillar density in HCM mut may be due to the sarcomere gene mutations. Overall, our data show that the extent of cellular hypertrophy and structural remodeling is more severe in HCM mut compared with HCM smn .
Cellular remodeling versus intrinsic sarcomere defect
Our study revealed a consistent and significant decrease in maximal force generating capacity of cardiomyocytes in manifest HCM patients harboring thin and thick filament mutations. This decrease is in line with previous results in human myocardium harboring thick myofilament mutations. 12, 19, 25, 29 The present study shows that an increase in cardiomyocyte hypertrophy and reduction in myofibrillar density represent major causes of the decrease in cardiomyocyte maximal force in HCM patients. The influence of the sarcomeric gene mutations on maximal force generating capacity was investigated by correcting cardiomyocyte F max for the decrease in myofibrillar density ( Figure 5 ). In HCM patients with mutations in MYBPC3 and TNNI3 the drop in F max could be largely ascribed to structural cellular changes as maximal force was similar to values observed in non-failing hearts after correction for myofibrillar density.
Interestingly, the reduction in maximal force generating capacity in the cardiomyocytes harboring mutations in MYH7, TPM1 and TNNT2 is partly caused by altered intrinsic properties of the sarcomeres. Low maximal force in tissue harboring mutations in MYH7, TPM1 and TNNT2 was confirmed in single human myofibrils (Figure 6 ), indicating that the sarcomere mutation itself causes a contractile deficit. The MYH7 mut group included patients with mutations in the two main domains of β-MyHC, the S1 (motor) domain and the rod domain. At the S1 domain actin-binding and ATP hydrolysis takes place. 30 Based on the central role of cMyHC in cross-bridge formation, it is likely that mutations in this protein could interfere with cross-bridge cycling and alter force generating capacity. Indeed, faster kinetics of actin-myosin interactions has been related to the low maximal force generating capacity of myofibrils from one HCM patient carrying the R403Q MYH7 mutation. 31 The rate of myofibril force generation following sudden Ca 2+ activation by fast solution switching (k act ), as well as k tr , were significantly faster in the R403Q patient compared with donors or control patients. The acceleration of the apparent cross-bridge kinetics associated with the MYH7 mutation was mainly due to acceleration of the rate with which cross-bridges leave the force generating states since the rate of the slow isometric phase of myofibril relaxation following sudden Ca 2+ removal (slow k rel ) was markedly accelerated. k act , k tr , and slow k rel are markedly faster or tend to be faster in myofibrils harboring other MYH7 mutations and the TNNT2 mutation reported here 32 19 Interestingly, the average kinetics of cross-bridge turnover of MYBPC3 mut myofibrils and cardiomyocytes are not accelerated and, on average, they are indistinguishable from those of donors (authors' unpublished results). Overall, this suggests that faster cross-bridge detachment can be responsible for the intrinsically lower force generating capacity of HCM sarcomeres harboring some specific missense mutations. Differences appeared between the myofibril force data ( Figure 6 ) and the corrected maximal force data in cardiomyocytes ( Figure 5 ). In general, force generating capacity of myofibrils was higher than that of cardiomyocytes. This difference could be caused by myofibrillar disarray in the cardiomyocytes leading to an inefficient force transmission from all myofibrils to the entire cardiomyocyte. Apart from the very low myofibril F max values in MYH7 mut and TPM1 mut , a slight reduction in F max was evident in all patient groups compared with non-failing donor myofibrils. This a-specific decrease in maximal force may be part of the disease-related hypertrophic remodeling and may involve post-translational sarcomere modifications other than the mutations. Both oxidation 33 and phosphorylation 34 have been associated with reduced maximal force generating capacity of sarcomeres and warrant future investigation. In addition, changes in Ca
2+
-handling may impair contractile performance of the heart in HCM. Recently, Coppini et al. 35 reported perturbations in intracellular Ca 2+ transients and several changes in ion channels and Ca
-handling proteins independent of the presence of a sarcomeric gene mutation. This indicates that the changes in Ca 2+ -handling are the result of a complex process of hypertrophic remodeling.
Opposite functional effects of MYH7 mutations, referred to as gain or loss of function, have been described in previous studies using in vitro assays and transgenic mice models as discussed by Lowey et al. 36 Initial studies on MYH7 mutations showed reduced velocity of actin movement over a layer of β-myosin molecules in an in vitro motility assay which has been described as a "loss of function". [36] [37] [38] The "gain of function" has been based on a transgenic mouse model harboring the malignant R403Q mutation in MYH7. 39 In the latter study, an increase in actin-activated ATPase activity and actin velocity was defined as "gain of function". We were able to study force characteristics of cardiomyocytes and myofibrils from multiple human cardiac samples harboring a MYH7 mutation. Our data are in favor of a loss of function. Discrepant functional effects caused by MYH7 mutations may depend on the myosin heavy chain isoform present in the ventricle. Rodents mostly express α-MyHC in the ventricles, while β-MyHC is predominant in larger animals and in human ventricles.
39,40
Interestingly, it has been shown that the R403Q MYH7 mutation leads to a gain of function in a transgenic mouse model with a α-MyHC background, while a loss of function was found when the mutation was present in mice with a β-MyHC background. 39 Only recently, Lowey and colleagues studied the effects of the R403Q mutation on a background of α-MyHC and β-MyHC in an in vitro assay. 41 Consistent with the studies in the transgenic mouse model, 39 it was shown that the effect of the R403Q mutation highly depends on the myosin isoform backbone. Based on the in vitro kinetic studies, Lowey et al. hypothesized that the R403Q MYH7 mutation will most likely lead to functional impairment in human cardiac β-MyHC. Indeed, our study in HCM patient samples provides evidence that MYH7 mutations lead to a loss of function in human sarcomeres, and stress the importance of human studies or transgenic rodent studies with a human-like background. Low maximal force generating capacity was also found at submaximal [Ca 2+ ] in MYH7 mut (Figure 7B ). At the end of the previous century it was already suggested that a contractile deficit caused by HCM sarcomeric gene mutations would trigger compensatory hypertrophy and represents the primary event that initiates disease. 42 , 43 Marian 43 proposed that decreased cardiomyocyte contractility provides the primary stimulus for increased trophic factors in the heart leading to hypertrophy based on in vitro studies that showed reduced contractile performance in adult cardiac cardiomyocytes expressing HCM mutations. 44, 45 However, hypocontractility may be paralleled by other phenomena which initiate and contribute to phenotype progression in HCM. One possible disease trigger that has been proposed is that of energy depletion. Crilley et al. 46 revealed with P 31 NMR a decrease in the PCr/ATP ratio independent of sarcomeric gene mutation and LV hypertrophy in HCM patients compared with controls. This decrease implies that there is a mismatch of ATP supply and utilization in the heart, which could lead to an energetic compromise sufficient to induce pro-hypertrophic pathways. Recently, we have shown that lengthdependent activation of myofilaments is perturbed by HCM-associated missense mutations. 47 The diverse functional changes seem to depend on the affected gene and the type and location of the mutation. The loss of function, characterized by the lower maximal force generating capacity of MYH7 mut sarcomeres, could be an initial trigger of disease pathogenesis. To establish if severe contractile dysfunction causes hypertrophy and to identify gene mutation-specific patterns of ventricular remodeling longitudinal studies are required of early stage mutation-positive, phenotype-negative cohorts on the clinical side.
Limitations and clinical implications
To our knowledge this is the first study in which the functional properties of cardiomyocytes and myofibrils were investigated from human HCM tissue harboring a wide range of thick and thin filament gene mutations. As cardiac remodeling is asymmetric in HCM, tissue heterogeneity may have been overlooked in our study. However, in previous studies we have shown that the variation between different pieces from one heart sample did not differ between HCM and donor hearts. 48 Moreover, multiple preparations from the same heart were analyzed in the different functional and histological assays (cardiomyocytes, myofibrils, histological slides) to exclude variation due to tissue heterogeneity in our studies.
Most patients (N=28) had a MYBPC3 mutation. This is partly explained by the high incidence of MYBPC3 founder mutations in the Netherlands. 12, 19 In addition, the risk of sudden cardiac death is higher in patients with TNNT2 mutations and cardiac hypertrophy is less frequently observed in these patients. 49 Thus, patients with TNNT2 mutations rarely undergo Morrow surgery. In fact, the mutation in the TNNT2 mut patient was homozygous and the heart was collected during transplantation surgery because of end-stage heart failure, which is in line with previous reports on patients with severe and progressive forms of HCM with two/multiple mutations. 50 Our study revealed structural differences between HCM mut and HCM smn with less hypertrophy and a minor decrease in myofibrillar density in HCM smn . A difference between genotype-positive and genotype-negative HCM patients was also reported by Olivotto and colleagues, who showed a more severe impairment of microvascular function in sarcomere mutation-positive compared to sarcomere mutation-negative individuals. 51 In order to optimise treatment of HCM patients, future studies are warranted to further explore differences in myocardial remodeling in sarcomere mutation-positive and mutation-negative HCM patients.
In conclusion, despite the relatively low number of patients in some of the gene mutation groups, sarcomere mutation-positive HCM patients showed reduced maximal force generating capacity of cardiomyocytes, which was largely explained by cardiomyocyte hypertrophy and reduced myofibrillar density. While cardiomyocyte remodeling and the associated reduction in F max are secondary consequences of HCM disease, hypocontractile sarcomeres may represent the initial trigger of disease pathogenesis in MYH7 mutation carriers.
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Supplementary material Histology
Supplementary Figure 1A shows representative haematoxylin and eosin stained slides of HCM mut , HCM smn and donor. The non-parametrical Kruskal Wallis test and Dunn's procedure revealed a significantly higher CSA in HCM mut compared to HCM smn and donor. In addition, the CSA of HCM smn was significantly higher compared to donor (Supplementary Figure 1B) . 
